Acinetobacter baumannii: A Drug-Resistant ICU Pathogen and How It Is Identified

In an intensive care unit, a patient on a ventilator develops a new pneumonia. The organism grown from the breathing tube turns out to be resistant to almost every antibiotic the laboratory tests, including the carbapenems usually held in reserve for the worst infections. This is Acinetobacter baumannii, an organism that survives on hospital surfaces for weeks, spreads through an ICU, and has become one of the hardest bacteria in the world to treat.

Acinetobacter causes little trouble for healthy people. Its danger is almost entirely in hospitals, in the sickest patients, and it is feared not because it is especially aggressive but because it is so hard to kill, both on surfaces and with antibiotics. This page is about how it causes infection, why it is so resistant, and how the laboratory identifies it.

What is Acinetobacter baumannii?

Acinetobacter is a group of Gram-negative bacteria found widely in soil, water, and dry environments. Most species cause little or no disease in healthy people. The medically important one is Acinetobacter baumannii, which causes the great majority of Acinetobacter infections and is a leading cause of hospital-acquired infection, especially in intensive care units.

Its risk is almost entirely to patients who are already vulnerable: those on ventilators, those with urinary catheters or other invasive devices, those with a long hospital stay, and people with weakened immunity, diabetes, or chronic lung disease. Healthy people are rarely affected. Acinetobacter can also simply live on the skin or in a wound or tracheostomy without causing infection (colonization), which is important because a positive culture does not always mean infection.

Which diseases does Acinetobacter baumannii cause?

A. baumannii causes a range of hospital infections. The most important are ventilator-associated pneumonia and catheter-related bloodstream infection. It also causes wound infections (including in combat and disaster injuries), urinary tract infection, and, less often, meningitis after neurosurgery. The clinical picture depends on the site; what unites these infections is that they occur in vulnerable, hospitalized patients and are often very hard to treat.

How does Acinetobacter baumannii cause disease?

Acinetobacter baumannii is not an aggressive, toxin-producing pathogen. It succeeds by persisting, spreading, and resisting, the profile of a survivor rather than an attacker. Each factor below explains part of that.

Survival on dry surfaces (the key trait). Most Gram-negative bacteria die quickly once a surface dries out. A. baumannii is unusual: it can survive on dry, inanimate surfaces, bed rails, monitors, ventilator equipment, for days to weeks. It means the organism lingers in the ICU environment and keeps re-infecting patients long after the first case. Its resistance to drying is why Acinetobacter outbreaks are so hard to stop and why environmental cleaning is central to control.

Biofilm formation. Like Serratia, A. baumannii forms biofilms on plastic and glass, on catheters, ventilator tubing, and other devices. The biofilm shields it from both antibiotics and the immune system and acts as a reservoir that keeps seeding infection. Biofilm on a breathing tube is a direct route to ventilator-associated pneumonia.

Capsule and cell surface. A polysaccharide capsule helps it resist phagocytosis and complement, contributing to its ability to survive in the blood and cause bacteremia.

Endotoxin (LPS) and iron acquisition. Its lipopolysaccharide drives the inflammatory response of sepsis, and siderophores let it scavenge iron from the host so it can grow where iron is scarce.

Putting it together

A. baumannii survives on dry ICU surfaces and equipment, spreads to patients on the hands of staff and via contaminated devices, and forms biofilm on catheters and breathing tubes. Once established in a vulnerable patient, its capsule and LPS help it survive and provoke inflammation, producing pneumonia or bloodstream infection. It rarely infects the healthy because it depends on a breached barrier (a tube, a wound) and a weakened host.

How is Acinetobacter identified in the laboratory?

Gram stain. Acinetobacter is a Gram-negative coccobacillus, short and plump, often appearing in pairs. On a Gram film it can be mistaken for Neisseria (a Gram-negative coccus) or for an enteric rod, so morphology alone is not enough.

The two tests that place it. Acinetobacter is separated from the Enterobacteriaceae by two features:

• It is oxidase-negative but does not ferment sugars (it is non-fermentative, or oxidative/asaccharolytic on the O/F test). The Enterobacteriaceae are also oxidase-negative but they ferment glucose. So a non-fermenting, oxidase-negative Gram-negative rod is not an enteric organism; think Acinetobacter (or another non-fermenter).
• It is non-motile. The name itself means "non-motile rod" (from the Greek akineto, unable to move). This separates it from motile non-fermenters.

Put together with Pseudomonas, the contrast is clean: Pseudomonas is oxidase-positive and motile; Acinetobacter is oxidase-negative and non-motile. Both are non-fermenters.

The identification panel

A practical note: on MacConkey agar Acinetobacter grows as pale, non-lactose-fermenting colonies (it does not ferment lactose), which can make it look superficially like a non-lactose enteric organism until the oxidase and O/F tests sort it out.

Why is Acinetobacter so drug-resistant?

Acinetobacter baumannii is one of the most antibiotic-resistant bacteria in medicine. Carbapenem-resistant A. baumannii is classified by the WHO as a critical-priority pathogen, the highest category, meaning new antibiotics against it are urgently needed. Understanding why it is resistant matters more than memorizing a drug list.

Its resistance comes from several mechanisms working together:

• Carbapenemase enzymes (especially OXA-type enzymes) that destroy carbapenems, the drugs usually reserved for the most serious Gram-negative infections.
• Multiple beta-lactamases that defeat penicillins and cephalosporins.
• Efflux pumps that actively pump many different antibiotic classes back out of the cell.
• Reduced membrane permeability (loss of porins) that keeps drugs from getting in.
• The ability to acquire resistance genes readily from other bacteria.

Because these mechanisms stack, a single strain is often resistant to almost every class at once. This is what "multidrug-resistant" (MDR), "extensively drug-resistant" (XDR), and even "pan-drug-resistant" A. baumannii mean, and why carbapenem resistance in this organism usually signals resistance to most other options too.

What treatment options remain for drug-resistant Acinetobacter?

When carbapenems fail, the drugs that may still work are limited, and the choice depends entirely on local susceptibility testing:

• Polymyxins (colistin, polymyxin B) often retain activity and are a mainstay against MDR strains, though they are older, more toxic drugs brought back out of necessity.
• Sulbactam, a beta-lactamase inhibitor, has useful direct activity against A. baumannii (unusual for this drug class) and is used, often in combination.
• Tigecycline and some aminoglycosides (amikacin) may retain activity in some strains.

The practical point for a student: there is no reliable empirical choice for MDR A. baumannii. Treatment must be guided by susceptibility testing, and infection control to prevent spread matters as much as the antibiotic. Specific doses and combinations are clinical decisions and are not covered here.

How can you remember Acinetobacter?

The name tells you the test. Acinetobacter means "non-motile rod." So one of its defining features, non-motility, is built into its name.

The non-fermenter that hides among the enterics. Acinetobacter is oxidase-negative and pale on MacConkey, just like a non-lactose enteric organism, so it can fool you at first glance. The tell is the O/F test: enterics ferment glucose, Acinetobacter does not.

Pseudomonas vs Acinetobacter: the oxidase split. Two big non-fermenting hospital pathogens. Pseudomonas is oxidase-positive and motile; Acinetobacter is oxidase-negative and non-motile. One test (oxidase) and one property (motility) separate the two.

The survivor, not the attacker. Acinetobacter is dangerous because it persists, on dry surfaces for weeks, in biofilms on tubes, and against almost every antibiotic, not because it is aggressive. Picture it clinging to a bed rail in the ICU, dry and alive, waiting. That image explains its outbreaks, its device infections, and why cleaning matters as much as drugs.

Carbapenem-resistant, critical priority. When carbapenems fail, you are near the end of the shelf. That is why WHO ranks carbapenem-resistant A. baumannii as a critical-priority pathogen, and why colistin, an old, toxic drug, has been brought back to treat it.

What are the key Acinetobacter exam facts?

Where do students get confused about Acinetobacter?

Colonization vs infection. Acinetobacter often lives on skin, wounds, or tracheostomy sites without causing disease. A positive culture may mean the patient is merely colonized, not infected. Treating every isolate as an infection leads to unnecessary antibiotics.

It is not an Enterobacteriaceae. Acinetobacter is oxidase-negative and pale on MacConkey, which makes it resemble a non-lactose enteric organism. But it does not ferment glucose. Enterobacteriaceae ferment; Acinetobacter does not. The O/F test is the separator.

Acinetobacter vs Pseudomonas. Both are non-fermenting hospital pathogens, so students mix them up. The clean split: oxidase (Pseudomonas positive, Acinetobacter negative) and motility (Pseudomonas motile, Acinetobacter non-motile).

Coccobacillus can mimic Neisseria. On a Gram stain, plump Acinetobacter pairs can look like Gram-negative cocci and be mistaken for Neisseria. Culture and biochemistry sort it out; do not identify from the Gram film alone.

Why an old, toxic drug is first-line. Colistin was largely abandoned decades ago because of kidney toxicity, then brought back because so little else works against MDR Acinetobacter. Students are sometimes surprised that an "old" drug is a mainstay; it is a sign of how resistant this organism is, not a sign that colistin is ideal.

References

1. Tille, P. M. (2022). Bailey & Scott's Diagnostic Microbiology (15th ed.). Elsevier.
2. Procop, G. W., et al. (2017). Koneman's Color Atlas and Textbook of Diagnostic Microbiology (7th ed.). Wolters Kluwer.
3. Lee, C. R., Lee, J. H., Park, M., Park, K. S., Bae, I. K., Kim, Y. B., Cha, C. J., Jeong, B. C., & Lee, S. H. (2017). Biology of Acinetobacter baumannii: pathogenesis, antibiotic resistance mechanisms, and prospective treatment options. Frontiers in Cellular and Infection Microbiology, 7, 55. https://doi.org/10.3389/fcimb.2017.00055
4. World Health Organization. (2024). WHO bacterial priority pathogens list, 2024. World Health Organization.